|
US10155038B2
(en)
|
2007-02-02 |
2018-12-18 |
Yale University |
Cells prepared by transient transfection and methods of use thereof
|
|
US9249423B2
(en)
|
2007-02-02 |
2016-02-02 |
Yale University |
Method of de-differentiating and re-differentiating somatic cells using RNA
|
|
US8956860B2
(en)
|
2009-12-08 |
2015-02-17 |
Juan F. Vera |
Methods of cell culture for adoptive cell therapy
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
IL288241B2
(en)
*
|
2012-06-11 |
2023-10-01 |
Wilson Wolf Mfg Corporation |
Improved cell culture methods for stress cell therapy
|
|
US9738696B2
(en)
|
2012-08-09 |
2017-08-22 |
The Board Of Trustees Of The Leland Stanford Junior University |
Superkines and synthekines: repurposed cytokines with new and enhanced signaling activities
|
|
AU2013204922B2
(en)
|
2012-12-20 |
2015-05-14 |
Celgene Corporation |
Chimeric antigen receptors
|
|
NZ711807A
(en)
*
|
2013-02-06 |
2020-06-26 |
Celgene Corp |
Modified t lymphocytes having improved specificity
|
|
PL2958943T3
(pl)
|
2013-02-20 |
2020-04-30 |
The Trustees Of The University Of Pennsylvania |
Leczenie nowotworu złośliwego za pomocą humanizowanego chimerycznego receptora antygenowego anty-egfrviii
|
|
ES2814962T3
(es)
|
2013-02-20 |
2021-03-29 |
Novartis Ag |
Fijación eficaz como objetivo de la leucemia humana primaria utilizando células T modificadas con receptor de antígeno quimérico anti-CD123
|
|
JP6493692B2
(ja)
|
2013-03-15 |
2019-04-10 |
セルジーン コーポレイション |
修飾されたｔリンパ球
|
|
ES3058841T3
(en)
|
2013-03-15 |
2026-03-13 |
Novartis Ag |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
|
TWI654206B
(zh)
|
2013-03-16 |
2019-03-21 |
諾華公司 |
使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
|
|
EP2986636B1
(en)
*
|
2013-04-17 |
2018-11-14 |
Baylor College Of Medicine |
Immunosuppressive tgf-beta signal converter
|
|
CN105431456A
(zh)
*
|
2013-06-14 |
2016-03-23 |
休斯敦系统大学 |
用修饰的嵌合抗原受体靶向肿瘤新生血管
|
|
EP3021853A1
(en)
|
2013-07-18 |
2016-05-25 |
Baylor College Of Medicine |
Method of enhancing potency of immune cells
|
|
JP6936934B2
(ja)
|
2013-09-24 |
2021-09-22 |
メディシナ セラピューティクス インコーポレイテッド |
インターロイキン−４受容体結合融合タンパク質及びその使用
|
|
CA2931684C
(en)
|
2013-12-19 |
2024-02-20 |
Novartis Ag |
Human mesothelin chimeric antigen receptors and uses thereof
|
|
EP4420663A3
(en)
|
2013-12-20 |
2024-10-30 |
Novartis AG |
Regulatable chimeric antigen receptor
|
|
EP4303229A3
(en)
|
2014-01-21 |
2024-04-17 |
Novartis AG |
Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
|
|
SI3888674T1
(sl)
|
2014-04-07 |
2024-08-30 |
Novartis Ag |
Zdravljenje raka z uporabo antigenskega himernega receptorja proti-CD19
|
|
CN106459924A
(zh)
*
|
2014-04-23 |
2017-02-22 |
得克萨斯州大学系统董事会 |
用于疗法中的嵌合抗原受体(car)及其制备方法
|
|
US10174095B2
(en)
|
2014-07-21 |
2019-01-08 |
Novartis Ag |
Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor
|
|
WO2016014553A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
|
SG10201913765YA
(en)
|
2014-07-21 |
2020-03-30 |
Novartis Ag |
Treatment of cancer using a cd33 chimeric antigen receptor
|
|
JP6736540B2
(ja)
|
2014-07-21 |
2020-08-05 |
ノバルティス アーゲー |
Ｃｌｌ−１キメラ抗原受容体を使用した癌の処置
|
|
JP6631865B2
(ja)
*
|
2014-08-11 |
2020-01-15 |
日本化薬株式会社 |
ＴＧＦβ阻害機能を持つキメラタンパク質
|
|
RU2020117196A
(ru)
|
2014-08-19 |
2020-10-15 |
Новартис Аг |
Химерный антигенный рецептор (car) против cd123 для использования в лечении злокачественных опухолей
|
|
JP6839074B2
(ja)
|
2014-09-17 |
2021-03-03 |
ノバルティス アーゲー |
養子免疫療法のためのキメラ受容体での細胞毒性細胞のターゲティング
|
|
CA2963935A1
(en)
|
2014-10-08 |
2016-04-14 |
Novartis Ag |
Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
|
|
MA41538A
(fr)
*
|
2014-10-17 |
2017-12-26 |
Baylor College Medicine |
Cellules immunitaires bipartites et tripartites de signalisation
|
|
IL253149B2
(en)
|
2014-12-29 |
2023-11-01 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
WO2016115482A1
(en)
|
2015-01-16 |
2016-07-21 |
Novartis Pharma Ag |
Phosphoglycerate kinase 1 (pgk) promoters and methods of use for expressing chimeric antigen receptor
|
|
AU2015380397B2
(en)
|
2015-01-31 |
2021-10-21 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for T cell delivery of therapeutic molecules
|
|
US11161907B2
(en)
|
2015-02-02 |
2021-11-02 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
|
US11596652B2
(en)
|
2015-02-18 |
2023-03-07 |
Enlivex Therapeutics R&D Ltd |
Early apoptotic cells for use in treating sepsis
|
|
US11512289B2
(en)
|
2015-02-18 |
2022-11-29 |
Enlivex Therapeutics Rdo Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
US11318163B2
(en)
|
2015-02-18 |
2022-05-03 |
Enlivex Therapeutics Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
US11304976B2
(en)
|
2015-02-18 |
2022-04-19 |
Enlivex Therapeutics Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
US11497767B2
(en)
|
2015-02-18 |
2022-11-15 |
Enlivex Therapeutics R&D Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
US11000548B2
(en)
|
2015-02-18 |
2021-05-11 |
Enlivex Therapeutics Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
ES2979088T3
(es)
|
2015-03-05 |
2024-09-24 |
Fred Hutchinson Cancer Center |
Proteínas de fusión inmunomoduladoras y usos de las mismas
|
|
WO2016154112A1
(en)
*
|
2015-03-20 |
2016-09-29 |
Children's National Medical Center |
Generating virus or other antigen-specific t cells from a naive t cell population
|
|
IL303972A
(en)
|
2015-04-08 |
2023-08-01 |
Novartis Ag |
CD20 treatments, CD22 treatments and combined treatments with CD19 chimeric antigen receptor expressing cell
|
|
WO2016168595A1
(en)
|
2015-04-17 |
2016-10-20 |
Barrett David Maxwell |
Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
|
|
EP4140492A1
(en)
|
2015-04-21 |
2023-03-01 |
Enlivex Therapeutics Rdo Ltd |
Therapeutic pooled blood apoptotic cell preparations and uses thereof
|
|
EP3286211A1
(en)
|
2015-04-23 |
2018-02-28 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
CN104910279B
(zh)
*
|
2015-06-05 |
2019-02-22 |
重庆精准生物技术有限公司 |
靶向癌胚抗原的嵌合抗原受体、慢病毒表达载体及其制备方法和应用
|
|
AU2016297014B2
(en)
|
2015-07-21 |
2021-06-17 |
Novartis Ag |
Methods for improving the efficacy and expansion of immune cells
|
|
US11667691B2
(en)
|
2015-08-07 |
2023-06-06 |
Novartis Ag |
Treatment of cancer using chimeric CD3 receptor proteins
|
|
GB201514875D0
(en)
|
2015-08-20 |
2015-10-07 |
Autolus Ltd |
Receptor
|
|
US11747346B2
(en)
|
2015-09-03 |
2023-09-05 |
Novartis Ag |
Biomarkers predictive of cytokine release syndrome
|
|
GB201518816D0
(en)
|
2015-10-23 |
2015-12-09 |
Autolus Ltd |
Receptor
|
|
IL259576B
(en)
|
2015-12-04 |
2022-09-01 |
Novartis Ag |
grna molecule containing tracr and crrna, pharmaceutical composition containing it and method for preparing cells for immunotherapy
|
|
US11413340B2
(en)
|
2015-12-22 |
2022-08-16 |
Novartis Ag |
Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapy
|
|
JP6884155B2
(ja)
|
2016-02-18 |
2021-06-09 |
エンリヴェックス セラピューティクス リミテッド |
癌治療のための併用免疫療法及びサイトカイン制御療法
|
|
US11325948B2
(en)
|
2016-03-19 |
2022-05-10 |
Exuma Biotech Corp. |
Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL
|
|
SG11201807286WA
(en)
*
|
2016-03-19 |
2018-10-30 |
F1 Oncology Inc |
Methods and compositions for transducing lymphocytes and regulated expansion thereof
|
|
US11111505B2
(en)
|
2016-03-19 |
2021-09-07 |
Exuma Biotech, Corp. |
Methods and compositions for transducing lymphocytes and regulating the activity thereof
|
|
US11549099B2
(en)
|
2016-03-23 |
2023-01-10 |
Novartis Ag |
Cell secreted minibodies and uses thereof
|
|
WO2018038945A1
(en)
|
2016-08-26 |
2018-03-01 |
Baylor College Of Medicine |
Constitutively active cytokine receptors for cell therapy
|
|
MY200337A
(en)
|
2016-10-07 |
2023-12-20 |
Novartis Ag |
Nucleic acid molecules encoding chimeric antigen receptors comprising a cd20 binding domain
|
|
ES2916335T3
(es)
|
2016-10-20 |
2022-06-30 |
Celgene Corp |
Receptores de antígeno quimérico heterodimerizable basados en cereblon
|
|
IL309526B2
(en)
|
2016-11-17 |
2025-02-01 |
2Seventy Bio Inc |
TGFBeta signal converter
|
|
EP3574005B1
(en)
|
2017-01-26 |
2021-12-15 |
Novartis AG |
Cd28 compositions and methods for chimeric antigen receptor therapy
|
|
GB201702617D0
(en)
*
|
2017-02-17 |
2017-04-05 |
Autolus Ltd |
Receptor
|
|
SG10202109571PA
(en)
*
|
2017-03-03 |
2021-10-28 |
Exuma Biotech Corp |
Methods and compositions for transducing and expanding lymphocytes and regulating the activity thereof
|
|
US11725210B2
(en)
|
2017-03-17 |
2023-08-15 |
Fred Hutchinson Cancer Center |
Immunomodulatory fusion proteins and uses thereof
|
|
CA3054621A1
(en)
|
2017-03-22 |
2018-09-27 |
Novartis Ag |
Compositions and methods for immunooncology
|
|
CA3059634A1
(en)
|
2017-04-13 |
2018-10-18 |
Senti Biosciences, Inc. |
Combinatorial cancer immunotherapy
|
|
AU2018347796B2
(en)
|
2017-10-10 |
2025-07-24 |
Medicenna Therapeutics, Inc. |
IL-4-fusion formulations for treatment of central nervous system (CNS) tumors
|
|
US11999802B2
(en)
|
2017-10-18 |
2024-06-04 |
Novartis Ag |
Compositions and methods for selective protein degradation
|
|
WO2019109980A1
(zh)
*
|
2017-12-06 |
2019-06-13 |
科济生物医药（上海）有限公司 |
嵌合蛋白、表达嵌合蛋白的免疫效应细胞及其应用
|
|
CN112218651A
(zh)
|
2018-01-08 |
2021-01-12 |
诺华公司 |
用于与嵌合抗原受体疗法组合的免疫增强rna
|
|
EP3759132A1
(en)
*
|
2018-03-02 |
2021-01-06 |
Allogene Therapeutics, Inc. |
Inducible chimeric cytokine receptors
|
|
CN112119157B
(zh)
|
2018-03-06 |
2025-01-14 |
宾夕法尼亚大学董事会 |
前列腺特异性膜抗原car及其使用方法
|
|
WO2019239213A2
(en)
|
2018-06-01 |
2019-12-19 |
Medicenna Therapeutics Inc. |
Uses and methods for oncolytic virus targeting of il-4/il-13 and fusions thereof
|
|
EP3802579A1
(en)
*
|
2018-06-01 |
2021-04-14 |
The Board of Trustees of the Leland Stanford Junior University |
Il-13/il-4 superkines: immune cell targeting constructs and methods of use thereof
|
|
US20220403001A1
(en)
|
2018-06-12 |
2022-12-22 |
Obsidian Therapeutics, Inc. |
Pde5 derived regulatory constructs and methods of use in immunotherapy
|
|
JP7438988B2
(ja)
|
2018-06-13 |
2024-02-27 |
ノバルティス アーゲー |
Ｂｃｍａキメラ抗原受容体及びその使用
|
|
CN110615843B
(zh)
*
|
2018-06-20 |
2023-05-09 |
上海隆耀生物科技有限公司 |
一种包含第三信号受体的嵌合抗原受体及其应用
|
|
JP2022512766A
(ja)
|
2018-10-17 |
2022-02-07 |
センティ バイオサイエンシズ インコーポレイテッド |
組み合わせがん免疫療法
|
|
US11419898B2
(en)
|
2018-10-17 |
2022-08-23 |
Senti Biosciences, Inc. |
Combinatorial cancer immunotherapy
|
|
US20200147137A1
(en)
*
|
2018-11-08 |
2020-05-14 |
WUGEN, Inc. |
Compositions and methods for treatment of cancer
|
|
CN116479022A
(zh)
*
|
2018-12-12 |
2023-07-25 |
中南大学 |
一种重组car19-il24基因、慢病毒载体、car19-il24-t细胞及应用
|
|
CN113508128B
(zh)
*
|
2019-03-01 |
2025-11-04 |
艾洛基治疗公司 |
组成型活性嵌合细胞因子受体
|
|
CA3129862A1
(en)
|
2019-03-01 |
2020-09-10 |
Allogene Therapeutics, Inc. |
Chimeric cytokine receptors bearing a pd-1 ectodomain
|
|
EP4021582A1
(en)
|
2019-08-30 |
2022-07-06 |
Allogene Therapeutics, Inc. |
Chimeric cytokine receptors comprising tgf beta binding domains
|
|
AU2020336992A1
(en)
|
2019-08-30 |
2022-04-14 |
Yale University |
Compositions and methods for delivery of nucleic acids to cells
|
|
KR102275668B1
(ko)
*
|
2019-09-26 |
2021-07-12 |
충북대학교 산학협력단 |
면역신호의 변환이 가능한 키메릭 사이토카인 수용체, 이를 발현하는 면역세포 및 이의 항암 용도
|
|
IL292924A
(en)
|
2019-11-26 |
2022-07-01 |
Novartis Ag |
Chimeric antigen receptors cd19 and cd22 and their uses
|
|
CN114761037A
(zh)
|
2019-11-26 |
2022-07-15 |
诺华股份有限公司 |
结合bcma和cd19的嵌合抗原受体及其用途
|
|
TWI894211B
(zh)
|
2020-02-24 |
2025-08-21 |
美商異基因治療有限公司 |
具有增強活性之bcma car-t細胞
|
|
TW202146431A
(zh)
|
2020-02-25 |
2021-12-16 |
英商圭爾醫療有限公司 |
用於經工程化細胞之嵌合受體
|
|
KR20230079367A
(ko)
|
2020-08-31 |
2023-06-07 |
예일 유니버시티 |
핵산을 세포에 전달하기 위한 조성물 및 방법
|
|
CA3231615A1
(en)
*
|
2021-09-17 |
2023-03-23 |
Mikko SIURALA |
Chimeric antigen receptors comprising interleukin-9 receptor signaling domain
|
|
CN119546327A
(zh)
|
2022-04-08 |
2025-02-28 |
再生元制药公司 |
多部分受体和信号传导复合物
|
|
JP2025540052A
(ja)
|
2022-12-01 |
2025-12-11 |
イェール ユニバーシティー |
細胞内ペイロード送達用刺激応答性トレースレス操作プラットフォーム
|
|
CN120225568A
(zh)
*
|
2022-12-27 |
2025-06-27 |
广州瑞风生物科技有限公司 |
一种融合蛋白及其应用
|
|
EP4403580A1
(en)
|
2023-01-23 |
2024-07-24 |
Medizinische Hochschule Hannover |
Anti-entpd3 chimeric antigen receptor
|
|
IL322256A
(en)
|
2023-01-23 |
2025-09-01 |
Medizinische Hochschule Hannover |
Anti-ENTPD3 chimeric antigen receptor
|
|
IL322333A
(en)
|
2023-02-07 |
2025-09-01 |
Quell Therapeutics Ltd |
Culture method for TREG cells
|
|
EP4420676A1
(en)
|
2023-02-24 |
2024-08-28 |
Medizinische Hochschule Hannover |
Chimeric antigen receptor
|
|
WO2024175805A1
(en)
|
2023-02-24 |
2024-08-29 |
Medizinische Hochschule Hannover |
Chimeric antigen receptor
|
|
CN116284449B
(zh)
*
|
2023-02-27 |
2024-11-19 |
深圳市先康达生命科学有限公司 |
增强型TGF-βR嵌合受体及其应用
|
|
JP2026507228A
(ja)
|
2023-03-03 |
2026-02-27 |
アーセナル バイオサイエンシズ インコーポレイテッド |
Ｐｓｍａ及びｃａ９を標的とするシステム
|
|
WO2024194605A1
(en)
|
2023-03-17 |
2024-09-26 |
Quell Therapeutics Limited |
Treg therapy
|
|
EP4434539A1
(en)
|
2023-03-20 |
2024-09-25 |
Medizinische Hochschule Hannover |
Chimeric antigen receptor
|
|
CN121586582A
(zh)
|
2023-03-20 |
2026-02-27 |
汉诺威医学院 |
嵌合抗原受体
|
|
WO2024193687A1
(en)
*
|
2023-03-23 |
2024-09-26 |
Nanjing Legend Biotech Co., Ltd. |
Inverted cytokine receptors and methods of use thereof
|
|
AU2024243972A1
(en)
*
|
2023-04-06 |
2025-10-23 |
Memorial Hospital For Cancer And Allied Diseases |
Il-10 receptor antibodies and methods of use thereof
|
|
CN116496417B
(zh)
*
|
2023-06-27 |
2023-10-10 |
北京市肿瘤防治研究所 |
含有膜型il7的融合蛋白及t细胞
|
|
WO2025016399A1
(en)
*
|
2023-07-17 |
2025-01-23 |
Nanjing Legend Biotech Co., Ltd. |
Fusion proteins and methods of use thereof
|
|
WO2026008994A1
(en)
|
2024-07-04 |
2026-01-08 |
Quell Therapeutics Limited |
Expression construct
|
|
GB202411558D0
(en)
|
2024-08-06 |
2024-09-18 |
Quell Therapeutics Ltd |
Culture method
|